Hu Zhou | Hematology | Excellence in Research Award

Published on by Global Academic Awards

Prof. Dr. Hu Zhou | Hematology | Excellence in Research Award

Henan Cancer Hospital | China

Prof. Dr. Hu Zhou is a leading hematology researcher recognized for his extensive work on the pathogenesis and clinical management of blood disorders, particularly immune thrombocytopenia, myelodysplastic syndromes, myeloproliferative neoplasms, and thrombosis–hemostasis abnormalities. With 621 citations, 78 published documents, and an h-index of 14, he has established a strong scholarly footprint in clinical and translational hematology. His research integrates clinical trials, molecular pathology, and mechanistic studies, contributing significantly to advances in immunoglobulin therapies, monoclonal antibodies, JAK2 inhibitors, and recombinant thrombopoietic agents. He has illuminated genetic polymorphisms, cytokine signaling pathways, and immune dysregulation mechanisms underlying chronic immune thrombocytopenia. His contributions further extend to leukemogenesis, epigenetic alterations in hematologic malignancies, and therapeutic optimization in refractory leukemia. As an active member of national and international hematology societies, he leads major funded research projects and has been recognized with multiple scientific achievement awards, reflecting his broad impact on hematologic innovation and patient-centered clinical advancement.

Profile: Scopus

Featured Publications

1. Zhou, H., et al. (2025). Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): A multicenter, single-arm, phase III trial. Clinical and Experimental Medicine.

2. Zhou, H., et al. (2025). Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: Multicentre, randomised, placebo-controlled, phase 2 trial. BMJ Clinical Research Edition.

3. Zhou, H., et al. (2025). Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open-label, multicenter study. Cancer.

4. Zhou, H., et al. (2025). Hetrombopag for patients with persistent primary immune thrombocytopenia: A post hoc analysis of a multicenter, randomized phase III trial. Research and Practice in Thrombosis and Haemostasis.

5. Zhou, H., et al. (2025). Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: A multicenter, randomised controlled trial (The TE-ITP Study). EClinicalMedicine.

Maria Agustina Perusini | Malignant Hematology Award | Best Researcher Award

Published on by Global Academic Awards

Dr. Maria Agustina Perusini | Malignant Hematology Award | Best Researcher Award

Dr. Maria Agustina Perusini, Princess Margaret Cancer Centre, Canada

Dr. Maria Agustina Perusini, MD 🩺, is a dedicated Clinical Research Fellow specializing in Leukemia and Myeloproliferative Neoplasms (MPN) at the Princess Margaret Cancer Centre, University of Toronto. With a background in Hematology and Internal Medicine from the University of Buenos Aires, Argentina 🇦🇷, she holds numerous certifications and awards in the field of Oncology. Dr. Perusini is recognized for her research on hematological disorders, particularly myelodysplastic syndromes (MDS) and acute lymphoblastic leukemia (ALL). She contributes actively to academic journals and has presented her findings at prestigious conferences worldwide 🌍.

 

Publication Profile

Scopus

Education

Dr. Maria Agustina Perusini, MD 🩺, has pursued an illustrious academic journey, culminating in a diverse array of post-doctoral degrees and a master’s in Clinical Epidemiology. With her foundation in Medicine from the esteemed Hospital Italiano Buenos Aires School of Medicine 🏥, she further specialized in Internal Medicine and Hematology at the University of Buenos Aires. Her thirst for knowledge led her to delve into the complexities of clinical epidemiology, focusing on Myelodysplastic Syndrome for her master’s thesis. Dr. Perusini’s dedication and commitment are evident in her successful completion of all coursework and requirements, showcasing her expertise in medical research and patient care.

Employment

Dr. Maria Agustina Perusini, MD 🩺, currently serves as a Clinical Research Fellow specializing in Leukemia and Myeloproliferative Neoplasms (MPN) at the prestigious Princess Margaret Cancer Centre, University of Toronto 🌟. In addition to providing active care in MPN and leukemia clinics, she undertakes crucial clinical and research responsibilities. Notably, Dr. Perusini holds the position of Chief Fellow in the Leukemia program, showcasing her leadership within the Division of Medical Oncology at the University of Toronto. Previously, she held roles including Junior Attending Physician and Hemato-Oncology Fellow Supervisor at the Hospital Italiano de Buenos Aires, Argentina 🇦🇷, demonstrating her extensive experience and commitment to healthcare.

 

Research Focus

Dr. Maria Agustina Perusini, MD 🩺, primarily focuses her research on hematological malignancies and their treatment outcomes. She has contributed significantly to studies investigating acute lymphoblastic leukemia (ALL), chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS), and their prognostic factors. Her work spans various aspects of these diseases, including the efficacy of treatment protocols such as asparaginase therapy and hematopoietic stem cell transplantation. Through her research, Dr. Perusini aims to improve understanding and management strategies for hematologic disorders, ultimately striving to enhance patient outcomes and quality of life.

 

Publication Top Notes: